A contract laboratory runs a sequence on a Friday: a concentrated system standard of one peptide, then three customer samples of a different peptide. On Monday, the report for the first customer sample shows a small unidentified peak at 11.2 minutes, which is exactly where the standard’s main peak eluted. The second and third samples show a smaller version of the same peak, and then it disappears. That pattern is a textbook description of carryover: material from an earlier run surfacing in a later one.
How residue survives between runs
Every sample in an HPLC sequence passes through the same autosampler needle, sample loop, valve, tubing and column. If any of those surfaces retains a trace of the previous sample, the next run can pick it up. The mechanism is adsorption, and peptides are good at it. Basic residues interact with residual silanols on silica and with exposed metal. Hydrophobic stretches cling to seals, rotor faces and polymer tubing. The same hydrophobicity that makes a sequence hard to elute from the column makes it hard to flush from the flow path.
Concentration order amplifies the effect. A trace left behind by a concentrated standard is a large fraction of a dilute sample that follows it. Running a high-concentration material immediately before a low-concentration one is the classic way to make carryover visible.
Recognizing the signature
Carryover has a distinctive fingerprint. The ghost peak appears at precisely the retention time of a major component from an earlier run, and it shrinks run by run as the system is flushed. A genuine impurity has no reason to line up with the previous sample’s main peak, and no reason to fade across a sequence.
| Observation | Points toward carryover | Points toward a real impurity |
|---|---|---|
| Retention time | Matches a major peak from the preceding run | Unrelated to earlier runs |
| Across a sequence | Shrinks with each following run | Constant in repeat runs of the same sample |
| Blank after the sample | Blank shows the same peak | Blank is clean |
| Change of run order | Peak moves or vanishes | Peak persists |
Two ways carryover distorts a result
In a purity determination, a carryover peak is integrated as an impurity, so the material is reported as less pure than it is. In an identity or trace analysis, the same peak suggests the presence of a compound that is simply not in the sample. Neither error has anything to do with the material in the vial; both are artifacts of the sequence.
Controls a laboratory uses
- Solvent blanks. A blank run immediately after a sample should show a flat baseline where that sample’s peaks eluted. Blanks bracketing a sequence are the basic control, and a method that omits them has a gap.
- A needle wash matched to the analyte. Most autosamplers rinse the needle between runs, but a mostly aqueous wash will not remove a hydrophobic peptide. The wash composition should suit the compounds being analyzed, and a wash that works for one analyte may fail for the next.
- Sensible run order. Dilute samples before concentrated ones, and blanks wherever unrelated compounds follow each other.
- A defined carryover check during method development. Running a blank directly after the highest-concentration standard shows how much residue the method leaves behind under worst-case conditions.
Carryover is usually expressed as the area of the ghost peak in the blank as a percentage of the corresponding peak in the preceding high-concentration run. That makes it comparable across methods and lets a laboratory decide whether the residue is small enough to ignore at the concentrations it actually analyzes. A carryover level that is harmless for a purity assay on concentrated material can be decisive for trace work, where the ghost peak may be as large as the signal being measured. The acceptable level therefore depends on what the method is for, not on a single universal figure.
These checks sit alongside the other pre-run controls a laboratory uses to show its system was fit for purpose on the day.
What this means when two reports differ
Suppose one laboratory’s chromatogram of a material shows a minor peak that another laboratory’s does not. That can reflect a real difference between samples, or it can reflect a difference between the sequences they were run in. Both laboratories may be reporting honestly; the same material was simply analyzed in different company. Carryover belongs on the list of reasons results disagree, together with column, gradient, detection wavelength and integration choices, which are covered in why suppliers report different peptide purity.
Reading a published chromatogram
A reader cannot prove carryover from a single trace, but a few features justify a question:
- A small peak with no corresponding entry in the impurity table.
- A peak the report declines to identify or explain.
- A minor peak that is present in one report and absent in another for the same product.
Asking whether blanks were run, and what came before the sample in the sequence, is a reasonable technical question for any laboratory. Our guides on how to read an HPLC chromatogram and HPLC method questions to ask a supplier go further. Each Battle Born product is analyzed by independent reverse-phase HPLC and the result is published for that product, so the trace is available to read with these points in mind.
Questions
What is HPLC carryover?
Residue from an earlier sample that remains in the autosampler, flow path or column and appears as a peak in a later run.
How can carryover be confirmed?
Run a solvent blank after the suspect sample. If the peak appears in the blank at the same retention time, carryover is the likely cause.
Are peptides especially prone to carryover?
Many are, because basic and hydrophobic residues adsorb to silica, metal and polymer surfaces in the flow path.
Does carryover make a material look less pure?
It can. A carryover peak integrated as an impurity lowers the reported area percent even though the material itself is unchanged.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.